Targeting the hepcidin-ferroportin axis to develop new treatment strategies for anemia of chronic disease and anemia of inflammation

A Potent Anti-Carcinoma and Anti-Acute Myeloblastic Leukemia Agent, AG490

(2012) Julio Caceres-Cortes   Anti-Cancer Agents in Medicinal Chemistry

Treatment of vitamin D deficiency in transfusion-dependent thalassemia

(2011) Ellen B. Fung et al.   AMERICAN JOURNAL OF HEMATOLOGY

Prevalence of 25-hydroxyvitamin D deficiency in subgroups of elderly persons with anemia: association with anemia of inflammation

(2011) T. S. Perlstein et al.   BLOOD

Pharmacologic inhibition of hepcidin expression reverses anemia of chronic inflammation in rats

(2011) I. Theurl et al.   BLOOD

Perturbation of hepcidin expression by BMP type I receptor deletion induces iron overload in mice

(2011) A. U. Steinbicker et al.   BLOOD

Hepcidin and iron regulation, 10 years later

(2011) T. Ganz   BLOOD

Inhibition of bone morphogenetic protein signaling attenuates anemia associated with inflammation

(2011) A. U. Steinbicker et al.   BLOOD

The specificities of small molecule inhibitors of the TGFß and BMP pathways

(2011) Janis Vogt et al.   CELLULAR SIGNALLING

Q: Is iron therapy for anemia harmful in the setting of infection?

(2011) E. DAOUD et al.   CLEVELAND CLINIC JOURNAL OF MEDICINE

The effects of changing vitamin D levels on anemia in chronic kidney disease patients: a retrospective cohort review

(2011) P.T. Lac et al.   CLINICAL NEPHROLOGY

Pharmacokinetics of Anti-hepcidin Monoclonal Antibody Ab 12B9m and Hepcidin in Cynomolgus Monkeys

(2010) Jim J. Xiao et al.   AAPS Journal

Delivery of siRNA Therapeutics: Barriers and Carriers

(2010) Jie Wang et al.   AAPS Journal

Malignancies in the setting of primary immunodeficiency: Implications for hematologists/oncologists

(2010) Ralph S. Shapiro   AMERICAN JOURNAL OF HEMATOLOGY

Molecular Mechanisms of Hepcidin Regulation: Implications for the Anemia of CKD

(2010) Jodie L. Babitt et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

Iron Homeostasis and the Inflammatory Response

(2010) Marianne Wessling-Resnick   Annual Review of Nutrition

Discovery and Development of Therapeutic Aptamers

(2010) P.R. Bouchard et al.   Annual Review of Pharmacology and Toxicology

A novel small-molecule disrupts Stat3 SH2 domain–phosphotyrosine interactions and Stat3-dependent tumor processes

(2010) Xiaolei Zhang et al.   BIOCHEMICAL PHARMACOLOGY

Antihepcidin antibody treatment modulates iron metabolism and is effective in a mouse model of inflammation-induced anemia

(2010) B. J. Sasu et al.   BLOOD

Heparin: a potent inhibitor of hepcidin expression in vitro and in vivo

(2010) M. Poli et al.   BLOOD

Hepcidin induction by transgenic overexpression of Hfe does not require the Hfe cytoplasmic tail, but does require hemojuvelin

(2010) P. J. Schmidt et al.   BLOOD

Down-regulation of hepcidin resulting from long-term treatment with an anti-IL-6 receptor antibody (tocilizumab) improves anemia of inflammation in multicentric Castleman disease

(2010) S.-N. J. Song et al.   BLOOD

Two to Tango: Regulation of Mammalian Iron Metabolism

(2010) Matthias W. Hentze et al.   CELL

Role of the hypoxia inducible factors HIF in iron metabolism

(2010) Carole Peyssonnaux et al.   CELL CYCLE

Bone Morphogenetic Proteins: A critical review

(2010) Beth Bragdon et al.   CELLULAR SIGNALLING

BMP6 Treatment Compensates for the Molecular Defect and Ameliorates Hemochromatosis in Hfe Knockout Mice

(2010) Elena Corradini et al.   GASTROENTEROLOGY

Hereditary Hemochromatosis: Pathogenesis, Diagnosis, and Treatment

(2010) Antonello Pietrangelo   GASTROENTEROLOGY

Polyetheylenimine-Polyplexes of Spiegelmer NOX-A50 Directed against Intracellular High Mobility Group Protein A1 (HMGA1) Reduce Tumor Growthin Vivo

(2010) Christian Maasch et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Siltuximab, a Novel Anti–Interleukin-6 Monoclonal Antibody, for Castleman's Disease

(2010) Frits van Rhee et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III, Randomized Study of the Effects of Parenteral Iron, Oral Iron, or No Iron Supplementation on the Erythropoietic Response to Darbepoetin Alfa for Patients With Chemotherapy-Associated Anemia

(2010) David P. Steensma et al.   JOURNAL OF CLINICAL ONCOLOGY

Natural and synthetic STAT3 inhibitors reduce hepcidin expression in differentiated mouse hepatocytes expressing the active phosphorylated STAT3 form

(2010) Nadia Fatih et al.   JOURNAL OF MOLECULAR MEDICINE-JMM

Vitamin D supplementation and recombinant human erythropoietin utilization in vitamin D-deficient hemodialysis patients

(2010) Victoria A. Kumar et al.   JOURNAL OF NEPHROLOGY

Impact of Erythropoiesis-Stimulating Agents on Energy and Physical Function in Nondialysis CKD Patients With Anemia: A Systematic Review

(2009) Shravanthi R. Gandra et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

Regulation of Hepcidin and Iron-Overload Disease

(2009) Pauline L. Lee et al.   Annual Review of Pathology-Mechanisms of Disease

Contribution of STAT3 and SMAD4 pathways to the regulation of hepcidin by opposing stimuli

(2009) H. Huang et al.   BLOOD

The molecular basis of hepcidin-resistant hereditary hemochromatosis

(2009) A. Fernandes et al.   BLOOD

Identification of TWSG1 as a second novel erythroid regulator of hepcidin expression in murine and human cells

(2009) T. Tanno et al.   BLOOD

Regulation of iron homeostasis in anemia of chronic disease and iron deficiency anemia: diagnostic and therapeutic implications

(2009) I. Theurl et al.   BLOOD

Interaction of the Hereditary Hemochromatosis Protein HFE with Transferrin Receptor 2 Is Required for Transferrin-Induced Hepcidin Expression

(2009) Junwei Gao et al.   Cell Metabolism

Hepcidin--A Potential Novel Biomarker for Iron Status in Chronic Kidney Disease

(2009) J. Zaritsky et al.   Clinical Journal of the American Society of Nephrology

The RGM/DRAGON family of BMP co-receptors

(2009) Elena Corradini et al.   CYTOKINE & GROWTH FACTOR REVIEWS

Hepcidin targets ferroportin for degradation in hepatocytes

(2009) G. Ramey et al.   HAEMATOLOGICA

STAT3 signaling within hepatocytes is required for anemia of inflammation in vivo

(2009) Ryotaro Sakamori et al.   JOURNAL OF GASTROENTEROLOGY

Plasma hepcidin levels are elevated but responsive to erythropoietin therapy in renal disease

(2009) Damien R. Ashby et al.   KIDNEY INTERNATIONAL

Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials

(2009) Julia Bohlius et al.   LANCET

BMP6 orchestrates iron metabolism

(2009) Clara Camaschella   NATURE GENETICS

Lack of the bone morphogenetic protein BMP6 induces massive iron overload

(2009) Delphine Meynard et al.   NATURE GENETICS

BMP6 is a key endogenous regulator of hepcidin expression and iron metabolism

(2009) Billy Andriopoulos Jr et al.   NATURE GENETICS

A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease

(2009) Marc A. Pfeffer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tocilizumab, a humanized anti-interleukin-6 receptor antibody, improved anemia in monkey arthritis by suppressing IL-6-induced hepcidin production

(2009) Misato Hashizume et al.   RHEUMATOLOGY INTERNATIONAL

Iron Sequestration and Anemia of Inflammation

(2009) Tomas Ganz et al.   SEMINARS IN HEMATOLOGY

Is the iron regulatory hormone hepcidin a risk factor for alcoholic liver disease?

(2009) Duygu-Dee Harrison-Findik   WORLD JOURNAL OF GASTROENTEROLOGY

Late Onset of Ccl2 Blockade with the Spiegelmer mNOX-E36–3′PEG Prevents Glomerulosclerosis and Improves Glomerular Filtration Rate in db/db Mice

(2008) Volha Ninichuk et al.   AMERICAN JOURNAL OF PATHOLOGY

Structure–activity relationship study of bone morphogenetic protein (BMP) signaling inhibitors

(2008) Gregory D. Cuny et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Hemojuvelin regulates hepcidin expression via a selective subset of BMP ligands and receptors independently of neogenin

(2008) Y. Xia et al.   BLOOD

Immunoassay for human serum hepcidin

(2008) T. Ganz et al.   BLOOD

Two BMP responsive elements, STAT, and bZIP/HNF4/COUP motifs of the hepcidin promoter are critical for BMP, SMAD1, and HJV responsiveness

(2008) J. Truksa et al.   BLOOD

Fine Tuning of Hepcidin Expression by Positive and Negative Regulators

(2008) Martina U. Muckenthaler   Cell Metabolism

The Transferrin Receptor Modulates Hfe-Dependent Regulation of Hepcidin Expression

(2008) Paul J. Schmidt et al.   Cell Metabolism

Venous Thromboembolism and Mortality Associated With Recombinant Erythropoietin and Darbepoetin Administration for the Treatment of Cancer-Associated Anemia

(2008) Charles L. Bennett   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Darbepoetin Alfa for the Treatment of Anemia in Patients With Active Cancer Not Receiving Chemotherapy or Radiotherapy: Results of a Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study

(2008) Robert E. Smith et al.   JOURNAL OF CLINICAL ONCOLOGY

A bone morphogenetic protein (BMP)-responsive element in the hepcidin promoter controls HFE2-mediated hepatic hepcidin expression and its response to IL-6 in cultured cells

(2008) Maria Vittoria Verga Falzacappa et al.   JOURNAL OF MOLECULAR MEDICINE-JMM

Anti-Ccl2 Spiegelmer Permits 75% Dose Reduction of Cyclophosphamide to Control Diffuse Proliferative Lupus Nephritis and Pneumonitis in MRL-Fas(lpr) Mice

(2008) O. Kulkarni et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Ferric Gluconate Reduces Epoetin Requirements in Hemodialysis Patients with Elevated Ferritin

(2008) T. Kapoian et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

BMP type I receptor inhibition reduces heterotopic ossification

(2008) Paul B Yu et al.   NATURE MEDICINE

The Anemia of Inflammation/Malignancy: Mechanisms and Management

(2008) J. W. Adamson   Hematology-American Society of Hematology Education Program